Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

885 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation.
Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, Kato K, Okamura A, Kikuta A, Fukuda T. Yakushijin K, et al. Among authors: okamura a, okamura h. Bone Marrow Transplant. 2019 May;54(5):674-680. doi: 10.1038/s41409-018-0304-4. Epub 2018 Aug 20. Bone Marrow Transplant. 2019. PMID: 30127466 Clinical Trial.
Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation.
Yakushijin K, Yamamoto K, Kurata K, Miyata Y, Kakiuchi S, Tomioka H, Kawamori-Iwamoto Y, Inui Y, Sanada Y, Okamura A, Murayama T, Matsuoka H, Minami H. Yakushijin K, et al. Among authors: okamura a. Int J Hematol. 2013 Feb;97(2):284-6. doi: 10.1007/s12185-012-1248-x. Epub 2013 Jan 8. Int J Hematol. 2013. PMID: 23297121
Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T. Nakane T, et al. Among authors: okamura a. Int J Hematol. 2017 Apr;105(4):485-496. doi: 10.1007/s12185-016-2154-4. Epub 2016 Dec 9. Int J Hematol. 2017. PMID: 27943166 Clinical Trial.
Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease.
Nishikawa S, Okamura A, Yamamori M, Minagawa K, Kawamori Y, Kawano Y, Kawano H, Ono K, Katayama Y, Shimoyama M, Matsui T. Nishikawa S, et al. Among authors: okamura a. Transplant Proc. 2009 Nov;41(9):3873-6. doi: 10.1016/j.transproceed.2009.06.231. Transplant Proc. 2009. PMID: 19917404
Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients.
Kurata K, Yakushijin K, Okamura A, Yamamori M, Ichikawa H, Sakai R, Mizutani Y, Kakiuchi S, Miyata Y, Kitao A, Kawamoto S, Matsuoka H, Murayama T, Minami H. Kurata K, et al. Among authors: okamura a. Cancer Chemother Pharmacol. 2018 May;81(5):839-846. doi: 10.1007/s00280-018-3550-7. Epub 2018 Mar 6. Cancer Chemother Pharmacol. 2018. PMID: 29511796
Early lymphocyte recovery predicts clinical outcome after HSCT with mycophenolate mofetil prophylaxis in the Japanese population.
Kurata K, Yakushijin K, Mizuno I, Gomyo H, Okamura A, Ichikawa H, Sakai R, Mizutani Y, Kakiuchi S, Miyata Y, Kitao A, Sanada Y, Inui Y, Uryu K, Kawamoto S, Sugimoto T, Yamamoto K, Ito M, Matsuoka H, Murayama T, Minami H. Kurata K, et al. Among authors: okamura a. Int J Hematol. 2018 Jul;108(1):58-65. doi: 10.1007/s12185-018-2437-z. Epub 2018 Mar 22. Int J Hematol. 2018. PMID: 29569120
885 results